Policy Notices

• NIH Implementation of the Revised Federal-wide Research Terms and Conditions
  (NOT-OD-21-029)
  National Institutes of Health
  

General Notices

• Pre-Application Webinar for RFA-CA-20-054, Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)
  (NOT-CA-21-017)
  National Cancer Institute
  National Institute of Biomedical Imaging and Bioengineering
  

• Temporary Extension of Eligibility for the NIDDK K01 Mentored Research Scientist Development Award During the COVID-19 Pandemic
  (NOT-DK-20-054)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

Notice of Changes to Funding Opportunities

• Notice of NIA Withdrawal from Participation in NOT-MD-20-019 "Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities"
  (NOT-AG-20-056)
  National Institute on Aging
  

• Notice of NIA Withdrawal from Participation in NOT-MH-20-047 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus"
  (NOT-AG-20-057)
  National Institute on Aging
  

• Notice of NIA Withdrawal from Participation in NOT-OD-20-097 "Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences
  (NOT-AG-20-058)
  National Institute on Aging
  

• Notice of NIA Withdrawal from Participation in NOT-MH-20-053, "Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19"
  (NOT-AG-20-059)
  National Institute on Aging
  

• Notice of NIA Withdrawal from Participation in NOT-MD-20-022, "Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations"
  (NOT-AG-20-060)
  National Institute on Aging
  

• Notice of Clarification to NIEHS' Participation on PA-20-272, "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)"
  (NOT-ES-21-003)
  National Institute of Environmental Health Sciences
  

• Notice of Extension of the Expiration Date of PAR-18-771 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)"
  (NOT-HL-20-824)
  National Heart, Lung, and Blood Institute
  

• Notice of Extension of the Expiration Date of PAR-18-772 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)"
  (NOT-HL-20-825)
  National Heart, Lung, and Blood Institute
  

• Notice of Extension to PAR-18-554, "Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)"
  (NOT-MH-21-070)
  National Institute of Mental Health
  

• Notice of Extension to PAR-18-555, "Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)"
  (NOT-MH-21-071)
  National Institute of Mental Health
  

• Notice of Change: Corrected Application Forms and Extension of Application Due Date for RFA-RM-20-016, Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Training Program (U2R Clinical Trial Optional)
  (NOT-RM-21-009)
  Office of Strategic Coordination (Common Fund)
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Cellular Cancer Biology Imaging Research (CCBIR) Program (U54 Clinical Trial Not Allowed)
  (NOT-CA-21-016)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported PDX Development and Trial Centers Research Network (PDXNet)
  (NOT-CA-21-009)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Promoting Health, Safety, and Recovery Training for COVID-19 Essential Workers and their Communities
  (NOT-ES-21-002)
  National Institute of Environmental Health Sciences
  

• RESCINDED - Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)
  (NOT-HL-20-823)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest: Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)
  (NOT-OD-21-020)
  National Institutes of Health
  Food and Drug Administration
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

Funding Opportunities

• Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
  (PA-21-071)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Library of Medicine
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Due dates vary by awarding IC Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)
  (PAR-21-022)
  National Institute on Drug Abuse
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional)
  (PAR-21-023)
  National Institute on Drug Abuse
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): J?uly 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Initiative for Maximizing Student Development (IMSD) (T32 - Clinical Trial Not Allowed)
  (PAR-21-025)
  National Institute of General Medical Sciences
  Application Receipt Date(s): February 26, 2021; January 28, 2022; January 30, 2023, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32 - Clinical Trial Not Allowed)
  (PAR-21-026)
  National Institute of General Medical Sciences
  Application Receipt Date(s): January 30, 2023
  
  

• NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required)
  (PAR-21-041)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021.
  
  

• NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)
  (PAR-21-042)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021.
  
  

• NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)
  (PAR-21-043)
  National Eye Institute
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021.
  
  

• Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
  (PAR-21-056)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 22, 2021, June 22, 2021, February 22, 2022, June 22, 2022, February 22, 2023, and June 22, 2023.
  
  

• Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
  (PAR-21-057)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 22, 2021, June 22, 2021, February 22, 2022 June 22, 2022, February 22, 2023, June 22, 2023
  
  

• Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
  (PAR-21-058)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): February 22, 2021, June 22, 2021, February 22, 2022, June 22, 2022, February 22, 2023, and June 22, 2023
  
  

• Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
  (PAR-21-059)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): March 15, 2021, June 22, 2021, February 22, 2022, June 22, 2022, February 22, 2023, and June 22, 2023
  
  

• Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)
  (PAR-21-065)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is January 25, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)
  (PAR-21-066)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is January 25, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
  (PAR-21-067)
  National Cancer Institute
  Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is January 25, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Biological Testing Facility (X01 Clinical Trial Not Allowed)
  (PAR-21-078)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): January 15, 2021, July 15, 2021, ?January 14, 2022, July 15, 2022
  
  

• NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
  (PAR-21-079)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): January 07, 2024
  
  

• Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical trial not allowed)
  (PAR-21-080)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  National Institute of Nursing Research
  Application Receipt Date(s): Standard dates apply.
  
  

• Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)
  (PAR-21-081)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Environmental Health Sciences
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): Standard dates apply.
  
  

• Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)
  (RFA-CA-21-003)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
  (RFA-CA-21-004)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)
  (RFA-CA-21-005)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement
  
  

• Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
  (RFA-CA-21-006)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Diabetes Research Centers (P30 Clinical Trial Optional)
  (RFA-DK-20-025)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): May 20, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)
  (RFA-DK-20-033)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 31, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)
  (RFA-ES-21-001)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): February 26, 2021; February 24, 2022; February 24, 2023
  
  

• Contraceptive Development Research Centers Program (P50 Clinical Trial Optional)
  (RFA-HD-22-003)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
  (RFA-MH-21-105)
  National Institute of Mental Health
  Office of Research on Women's Health
  Application Receipt Date(s): February 9, 2021 All applications are due by 5:00 PM local time of applicant organization. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
  (RFA-MH-21-106)
  National Institute of Mental Health
  Office of Research on Women's Health
  Application Receipt Date(s): February 9, 2021 All applications are due by 5:00 PM local time of applicant organization. Alltypes of non-AIDS applicationsallowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R34 Clinical Trial Optional)
  (RFA-MH-21-150)
  National Institute of Mental Health
  National Institute on Drug Abuse
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
  
  

• Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R01 Clinical Trial Optional)
  (RFA-MH-21-151)
  National Institute of Mental Health
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.?
  
  

• Social Drivers of Mental Illnesses in Low- and Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional)
  (RFA-MH-21-160)
  National Institute of Mental Health
  Application Receipt Date(s): March 18, 2021 No late applications will be accepted for this Funding Opportunity Announcement.